Life at i-Pharm Before we wrap up, here's a look at what's been happening across life at i-Pharm this month
Editorial refresh Practical 2026 note for CJC For this peptide therapy page, the 2026 refresh focuses on tirzepatide, BPC-157, safety signals, cjc, 1295, combination so the article stays close to the question behind "CJC"
Key factors influencing cost include: Regulatory status: Licensed medicines that have undergone full MHRA or EMA approval typically command higher prices than older, off-patent alternatives, reflecting the investment in clinical development and post-marketing surveillance
Comparing the vial labels stated concentration against the prescribers written instructions is the most reliable way to catch a discrepancy early
Regarding the effect of GLP-1 on vascular endothelium, numerous in vitro studies and animal studies showed either nitric oxide-dependent or -independent vasodilative effects [121415192021]